A Phase 2, Randomized, Open-label Trial To Evaluate The Safety And Immunogenicity Of A Multivalent Pneumococcal Conjugate Vaccine Given With, Or Separately From, 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2019
Price : $35 *
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors Pfizer
- 25 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 14 Jun 2018 Status changed from not yet recruiting to recruiting.
- 14 Jun 2018 New trial record